

# Index

adolescent onset 167	IRAOS 128
see also onset of disease	Perceptual Aberration Scale (PAS) 369, 370
adoption studies 200–1 results 201	Peters Delusions Inventory (PDI) 372, 373 Present State Examination (PSE) 129, 372
Age, Beginning and Course (ABC) Schizophrenia	Psychosis Screening Questionnaire (PSQ) 371
Study 128, 133, 324, 327	373
comorbidity with alcohol and drug abuse 141–2	Research Diagnosis Criteria (RCD) 365
age effects 12	Schizotypal Personality Questionnaire (SPQ)
age-at-onset 167, 208	369, 370
gender differences 170–1	association 441
methodological issues 167–8	association studies 224–7, 441
substance abuse and 332	family-based 225–6
see also early-onset schizophrenia; onset of	genome-wide 228–9
disease; very-late-onset schizophrenia	methodological problems 226–7
Akaike Information Content (AIC) 245, 248	asylums, growth of 34–5
alcohol abuse 317, 320-1	Auditory–Vocal Association Test 115–16
as cause of schizophrenia 327	autism, MMR vaccine and 9
comorbidity 141–2, 150	
see also substance abuse	behavioural predictors of schizophrenia 107, 116
Alzheimer's disease 223, 226	bias 441
amphetamine abuse 324–5, 328	publication bias 444
see also drug abuse	recall bias 444
amyotrophic lateral sclerosis 282	selection bias 444
anastrophae phase 128	biometrical model fitting 202-5
antidepressant treatment, suicide prevention 306	results 204–5
apocalypse phase 128	birth complications see obstetric complications
apolipoprotein E (ApoE) 225–6	Bonn Scale for the Assessment of Basic Symptom
apopheny phase 128	(BSABS) 127–8, 129
appendicitis 282	brain structural abnormalities
assessment instruments	as markers of aetiological factors 254
Auditory-Vocal Association Test 115–16	detecting causes of 256–65
Bonn Scale for the Assessment of Basic	early-onset schizophrenia 177–8
Symptoms (BSABS) 127–8, 129	very-late-onset schizophrenia 178
Brief Limited Psychotic Symptoms (BLIPS)	see also cerebral structural abnormalities
129	Brief Limited Intermittent Psychotic Symptoms
Brief Psychiatric Rating Scale (BPRS) 131	(BLIPS) 129
Composite International Diagnostic Interview	Brief Psychiatric Rating Scale (BPRS) 131
(CIDI) 373	British National Psychiatric Morbidity Study 318
Comprehensive Assessment of At Risk Mental	
States (CAARMS) 128	cancer 278–80
Diagnostic and Statistical Manual (DSM) 365,	cannabis abuse 321–2
367, 373, 377, 379, 387, 398–9	as cause of schizophrenia 325-7, 328
Disability Assessment Schedule (DAS) 140	see also drug abuse; substance abuse
Global Assessment of Functioning (GAF) 129	cardiovascular disease 278
International Classification of Disease (ICD)	Caribbean studies 22
365, 367, 379, 387, 398–9	case-control study 441

447



categorical representations 377-9	psychosis transitions 375–7
validity of 379-80	psychotic symptom distribution 369
latent classes 386-90	psychotic symptom prevalence 369-73
traditional categories 382-6	delusions 371–3
category fallacy 59	hallucinations 370-1, 372-3
causality, new approaches to 89-90	similarity in underlying dimensional
longitudinal or life-course approach 89-90	representation 373-4
multilevel approach 90	Copenhagen High Risk Study 101, 108, 434
cerebral structural abnormalities 153-5	Copenhagen Obstetric High Risk Project 104
interpretation of changes 154	course of disease
static versus progressive change 154-5	early course
see also brain structural abnormalities	definition 131–2
cerebrospinal fluid to brain ratio 259	phase models 128–9
childhood developmental deficits 100-19	prognostic significance of 139–41
general population birth cohort studies 111-15	systematic retrospective analysis 133
genetic high-risk cohorts 101-11	see also prodrome
studies with information from adolescence	early-onset schizophrenia 180-1
108–11	first-episode studies 151–3
studies with information from infancy	geographical variation 22-8
102–4	service planning implications 416, 421
studies with information from middle	time trends 41–3
childhood 104-8	very-late onset schizophrenia 181
see also specific studies	see also onset of disease; outcome
childhood infection 78	criminal behaviour see violence
childhood onset 167	
see also early-onset schizophrenia; onset of	Danish High-Risk Project
disease	follow-up study 259–61
cigarette smoking 322–3	pilot study 257–9
see also substance abuse	delusions 371–2
cities see urban effects	cooccurrence with hallucinations 372-3
clozapine, suicidality and 306	depression
cocaine abuse 324–5, 328	prognostic significance 139, 140
see also drug abuse; substance abuse	suicide risk and 302
coeliac disease 282	prevention 306
cognitive predictors of schizophrenia 107-8, 115	Determinants of Outcome of Severe Mental
early-onset schizophrenia 178-9	Disorders (DOSMED) Study 19, 135-7
very-late-onset schizophrenia 179-80	see also Ten Country Study
cohort effects 12, 40-1	developing countries
cohort study 441-2	course of disease 23–8
collaborative ventures 90–1	incidence 18-23
community cohesion, outcome and 29	outcome 23–30
comorbidity	possible explanations for differences 29–30
first-episode studies 150	developmental deficits see childhood
service planning implications 416, 418, 419	developmental deficits
substance abuse 141-2, 150, 317-18	developmental epidemiology 71
international evidence 318-19	developmental insanity 71, 100
temporal and geographic variations 319-20	developmental risk factors 175, 434-5
see also alcohol abuse; drug abuse	diabetes mellitus 281
suicide risk and 302-3	diagnosis 364, 398-9
see also physical illness in schizophrenia	diagnostic criteria 37–40, 365
Composite International Diagnostic Interview	epidemiological perspective 365–6
(CIDI) 373	see also continuity hypothesis; dimensional
Comprehensive Assessment of At Risk Mental	hypothesis
States (CAARMS) 128	Diagnostic and Statistical Manual (DSM) criteria
confounding variables 89, 442	365, 367, 373, 377, 379, 387, 398–9
contextual factors 10	dimensional hypothesis 377–98
continuity hypothesis 366–77	grouping individuals 378–9
demographic risk factor associations 375	grouping symptoms 377–8
familial clustering and longitudinal associations	validity of dimensional and categorical
374–5	representations 379–98
perceptions of the psychosis continuum 367–9	discontinuity 380-2
causal risk factors and distribution 367–9	latent classes 386–90



symptom dimensions 390-8	family studies 195–7
traditional categories 382-6	results 196–7
Disability Assessment Schedule (DAS) 140	famine, prenatal 79
discontinuity 380-2	Finnish Adoptive Family Study of Schizophrenia
dizygotic twins 197-200, 246-9, 392	109, 210, 238
drug abuse 317, 321–3	first-episode studies 148–58
as cause of schizophrenia 324–8	advantages of 149
cannabis 321–2, 325–7	cerebral structural abnormalities 153-5
comorbidity 141-2, 150	interpretation of changes 154
migrants 61	static versus progressive change 154–5
nicotine 322–3, 327–8	comorbidity 150
opiates 322	course of disease 151–3
stimulants 322, 324–5	gender effects 150-1
urbanization and 54	methodological issues 155–7
see also substance abuse	definition of the first episode 155–6
Dunedin Multidisciplinary Health and	diagnostic dilemma 157
Developmental Survey 116–17	study population 156–7
duration of untreated psychosis (DUP) 152	outcome 151–3
aurunon or anti-cutcu poyenooto (2 01) 102	risk factors 150
early course of disease see course of disease	time trends in incidence 149–50
early-onset schizophrenia 167	treatment response 152
course of disease 180–1	Fish High-Risk Study 101, 102–3
outcome 180–1	11311 111gii 103K Ottudy 101, 102 3
phenomenology 171–2	gender differences
prevalence rates 168–9	age-at-onset 170–1
risk factors 173–80	first-episode studies 150–1
developmental 175	onset of disease 135–7
genetic 173–4	possible explanations for 137
neurocognitive impairment 178–9	substance abuse 332
pregnancy and birth complications 174–5	gene mapping strategies 222–7
premorbid social adjustment and personality	association studies 224–7
175–6	family-based 225–6
sensory impairment 176	methodological problems 226–7
structural brain abnormalities 177–8	gene–environment interaction consequences
treatment issues 181–2	249–50
see also onset of disease	linkage studies 223–4
ecological fallacy 442	gene–environment interaction 87–9, 210–11,
	235–51, 254–6, 442
ecological study 442	
economy, outcome and 29	additive interaction 239
Edinburgh High Risk Study 101, 110	consequences for gene mapping studies
effect 442	249–50
endophenotypes 442	consequences for risk studies 241–5
environmental factors, migrants 61	consequences for twin studies 245–9
see also gene–environment interaction; urban	correlation 236, 240–1
effects	genotype–perinatal hypoxia interaction 264–5
Epidemiologic Catchment Area (ECA) study 318,	multiplicative interaction 239–40
320, 356, 371	neuroimaging studies 254–66
epidemiology	detecting causes of brain structural changes
age-period-cohort effects 11-15	256–65
discrimination between 12–15	programming 87–9
effects at the individual level 8–9	synergism 236–9
effects at the societal level 9–11	generational effects 12
life-course effects 15	genetic basis 173–4, 193–4
molecular epidemiology 230	adoption studies 200–1
uses of epidemiological data 411–12	family studies 195–7
epilepsy 281–2	future research directions 227–31
ethnic minorities 60	functional studies 229
service planning 418	genetic testing 230–1
see also migration	genome-wide association studies 228–9
	molecular epidemiology 230
familial clustering 374–5	nosology 229–30
family relationships, outcome and 29	refining phenotypes 227



genetic basis (cont.)	mechanisms of association 78-9
gene mapping strategies 222–7	rubella 77–8
association studies 224-7	season of birth effect and 56-7
linkage studies 223–4	urbanization and 53-4
genetic risk factors 431–2	influenza
high-risk studies 197	prenatal exposure as risk factor 8, 75–7, 433
childhood developmental deficits 101-11	season of birth effect and 56-7
migrants 61	informal economies, outcome and 29
mode of inheritance 205, 221	inheritance, mode of 205, 221
nature of genetic effect 221–2	see also genetic basis
phenotypic abnormalities in relatives 209–10	intelligence quotient as predictor of schizophrenia
relative contribution of genetic and	107–8, 115
environmental factors 201–5	early-onset schizophrenia 178–9
biometrical model fitting 202–5	International Classification of Diseases (ICD)
correlations in liability 202	365, 367, 379, 387, 398–9
liability-threshold model 201–2	International Pilot Study of Schizophrenia (IPSS)
schizophrenia spectrum 206–7, 221	23, 27–8
service planning implications 414–15	International Study of Schizophrenia (ISoS) 28–9
specificity of genetic liability 205	IRAOS interview 128
splitting the schizophrenia syndrome 207–9	Israeli Draft Board Conscript Cohort 114
age at onset 208	Israeli High Risk Study 101, 104–6
schizophrenia subtypes 207	childhood predictors of later schizophrenia 105
symptom dimensions 207–8	protective factors 105–6
twin studies 197–200, 246–9, 392	I
discordant twin pairs 208–9	Jerusalem Infant Development Study (JIDS) 101,
see also gene—environment interaction	103
genetic testing 230–1 genome-wide association studies 228–9	language abnormalities as predictor of
e a constant of the constant o	language abnormalities, as predictor of
geographical variation course of disease 23–8	schizophrenia 115–16 late paraphrenia 167
incidence 18–23	liability correlations 202
outcome 23–30	liability-threshold model 201–2
explanations for differences 29–30	life-course effects 15, 89–90
Global Assessment of Functioning (GAF) 129	linkage 443
Global Assessment of Functioning (GMF) 129	linkage disequilibrium 222
hallucinations 370-1	linkage studies 223–4
cooccurrence with delusions 372–3	longitudinal approach 89–90
hallucinogen abuse 324–5	longitudinal associations 374–5
see also drug abuse	rongitudinar accomments 27 1 2
Helsinki Birth Cohort Studies 113–14, 261–5	MacArthur Violence Risk Assessment Study 355
brain changes 262	Maudsley Early Onset Schizophrenia Study 175,
perinatal hypoxia 263–4	177, 179
genotype interaction 264–5	Maudsley Family Study 209–10
heritability 443	Medical Research Council National Survey of
human immunodeficiency virus (HIV) 282	Health and Development 111–12
hypoxia, perinatal 263–4	meta-analysis 443
genotype interaction 264–5	misdiagnosis, in migrants 59
0 11	migration 58–62
immunization see vaccinations	historical context 58–9
incidence	methodological problems 59-60
geographical variation 18-23	category fallacy 59
season of birth influence 55-8, 75	different illness 60
time trends 34–41	estimating the denominator 59
cohort effects 40-1	misdiagnosis 59
first-episode studies 149–50	separating the effects of migration and
period effects 36–40	ethnicity 60
see also prevalence	possible causes of migration effect 61-2
individual patient data meta-analysis 443	drug abuse 61
infections	genes or environment 61
neonatal and childhood infection 41,78	neurodevelopmental impairment 61
prenatal exposure 41, 75–9, 433	social causation 61–2
influenza 8, 75–7, 433	urbanization 62



MMR vaccine, autism and 9	service planning implications 416-17
molecular epidemiology 230	stages of 134–5
monozygotic twins 197-200, 246-9, 392	symptoms of 137–8
mortality 273, 275-7	systematic retrospective analysis 133
cancer and 279	see also age-at-onset; early-onset schizophrenia;
death from natural causes 275-6	very-late-onset schizophrenia
service planning implications 416, 419	opiate abuse 322
see also suicide	see also drug abuse; substance abuse
motor coordination, as predictor of	outcome
schizophrenia 115	early-onset schizophrenia 180-1
multiple sclerosis 281	first-episode studies 151–3
	geographical variation 22-30
National Child Development Study 112-13	possible explanations for differences 29-30
National Collaborative Perinatal Project (NCPP),	community cohesion 29
Philadelphia 114–16	family relationships 29
childhood developmental variables as	informal economies 29
predictors of schizophrenia 115-16	segregation of the mentally ill 29
National Comorbidity Study, USA 318, 367	societal basis 30
National Institute of Mental Health (NIMH)	service planning implications 416
childhood-onset schizophrenia project 177	substance abuse effects 333-6
Epidemiologic Catchment Area (ECA) study	risk of violence 335
318, 320, 356, 371	use of services 333–5
NEMESIS study 373	time trends 41–3
neonatal infection 78	very-late-onset schizophrenia 181
nested case-control study 443	see also course of disease; mortality; suicide
neurodevelopmental hypothesis 71, 74, 100	•
neurodevelopmental impairment, migration effect	pandysmaturation (PDM) 103
and 61	Perceptual Aberration Scale (PAS) 369, 370
neuroleptics, suicide risk and 305-6	perinatal hypoxia 263-4
New York High Risk Project (NYHRP) 101,	genotype interaction 264–5
106–8	perinatal risk factors see obstetric complications
behavioural predictors 107	period effects 11–12, 36–40
cognitive predictors 107–8	personality, premorbid 175–6
neuropsychological predictors 106-7	substance abuse and 332-3
New York Infant Development Study 102-3	see also social disability
nicotine abuse 322–3	Peters Delusions Inventory (PDI) 372, 373
as cause of schizophrenia 327-8	phenotype 443
see also substance abuse	genetic validity 227
nonaffective acute remitting psychosis (NARP)	physical illness in schizophrenia 277-82
22–3	cancer 278–80
Northern Finland Birth Cohort (1966) 113	cardiovascular disease 278
nosology 229–30	diabetes mellitus 281
nutritional deficiency, prenatal 41, 433-4	epilepsy 281–2
//1	human immunodeficiency virus (HIV) 282
obstetric complications 116, 174-5, 255-6, 432-3	multiple sclerosis 281
case-control studies 81	rheumatoid arthritis 280-1
neuroimaging studies 259-61, 263-4	service planning implications 416, 419
perinatal hypoxia 263-4	suicide risk and 303
population-based studies 82-6	see also comorbidity
meta-analysis of findings 86	population attributable risk percent 443
methodological issues 82-3	population stratification 443
specificity 86	positional cloning 249
statistical power issues 83	predictors of schizophrenia 105, 106-8, 115-16
timing of exposure 83–6	behavioural predictors 107, 116
service planning implications 415	cognitive predictors 107-8, 115
urbanization and 53	early-onset schizophrenia 178-9
odds ratio 443	very-late-onset schizophrenia 179-80
onset of disease	language abnormalities 115–16
assessment of 132-3	motor variables 115
definition 131-2	neuropsychological predictors 106-7
gender differences 135–7	obstetric complications 116, 255-6
possible explanations for 137	see also risk factors



pregnancy complications see prenatal risk factors	first-episode studies 150
premorbid personality 175-6	for suicide see suicide
substance abuse and 332-3	genetic 173-4, 431-2
see also social disability	see also genetic basis
prenatal risk factors 75-81, 174-5, 432-3	prevention implications 428–9
famine 79	see also obstetric complications; predictors of
infections 75-9, 433	schizophrenia; prenatal risk factors; season
influenza 8, 75-7, 433	of birth effects; urban effects
mechanisms of association 78-9	risk-modifying factors 428
rubella 77–8	rubella, prenatal 77–8
nutritional deficiency 41, 433-4	
place of birth 75	schizophrenia spectrum 206-7, 221
rhesus incompatibility 79-80	schizotaxia hypothesis 103
stress 80–1	Schizotypal Personality Questionnaire (SPQ) 369
time of birth 75	370
Present State Examination (PSE) 129, 372	schizotypy 369, 374
prevalence	season of birth effects 55-8, 75, 432
early-onset schizophrenia 168-9	differences between summer- and winter-born
schizophrenia prevalence among general	patients 57–8
population suicides 290–2	possible causes of 56–7
very-late-onset schizophrenia 170	urban effect and 57
see also incidence	segregation analysis 444
prevention	segregation of the mentally ill, outcome and 29
future research 435–7	selection bias 444
possible preventive strategies 430-5	sensory impairment, as risk factor 176
indicated prevention 430-1	service planning
selective prevention 430	conceptual model 412
universal interventions 431-5	evidence-based approach 412-21
science of 427–30	at the level of catchment area 416-19
barriers to primary prevention 429-30	at the level of individual patients 414-16
risk factors and causes 428-9, 431-5	at the national/regional level 420-1
suicide 306, 307	uses of epidemiological data 411-12
prisoners, service planning 418	service use, substance abuse and 333-5
prodrome 124-31	single nucleotide polymorphism (SNP) 228
assessment of prodromal signs and symptoms	skin complexion 10–11
125–8	smoking 322–3
historical context 124–5	see also substance abuse
prospective validation of prodromal symptoms	social disability 140–1
129–31	early-onset schizophrenia and 175–6
see also course of disease	social isolation 176–7
proxy variables 89, 443	urbanization and 54–5
psychological autopsy 289–90	societal racism 10
Psychosis Screening Questionnaire (PSQ) 371,	sociodemographic risk factors for suicide 299
373	socioenvironmental influences 5–15, 29–30
psychosis transitions 375–7	migrants 61–2
psychosocial stress, urbanization and 54	see also urban effects
publication bias 444	speech abnormalities, as predictor of
	schizophrenia 115–16
quantitative trait locus (QTL) approaches 227	standardized mortality (morbidity) ratio 444
	stimulant abuse 322
recall bias 444	as cause of schizophrenia 324-5
relapse rates 152	see also drug abuse
service planning implications 421	stress, prenatal 80–1
see also course of disease	structural brain abnormalities see brain structural
relative risk 444	abnormalities
Research Diagnostic Criteria (RDC) 365	substance abuse 274, 317–18
residual confounding 444	as cause of schizophrenia 323–9
rhesus incompatibility 79-80	explanatory model 328–9
rheumatoid arthritis 280-1	temporal relationship 324
risk factors 444	characteristics of patients who abuse substances
demographic risk factor associations 375	332–3
developmental 175, 434-5	age at onset 332



premorbid personality 332-3	tardive dyskinesia 153–4
sex 332	Ten Country Study 19, 23–7
common factor underlying schizophrenia and	course and outcome 28
substance abuse 331–2	incidence 19-21
comorbidity 141-2, 150	time trends
international evidence 318-19	course of disease 41–3
temporal and geographic variations	incidence 34–41
319–20	age-period-cohort effects 36-41
effects on psychosis outcome 333–6	first-episode studies 149–50
risk of violence 335	outcome 41–3
use of services 333–5	treatment
future studies 336–7	early-onset schizophrenia 181–2
self-medication hypothesis 329–30	first episode 152
service planning implications 418	
social milieu effects 330–1	impact of 10
	service planning implications 417
suicide risk and 302–3	suicide risk and 304–6, 307
see also alcohol abuse; drug abuse	prevention 306
subtypes of schizophrenia 207, 379	very-late-onset schizophrenia 182–3
suicide risk and 302	see also prevention
suicide 273–4, 277, 288–308	trema phase 128
classification of 288–9	twin studies 197–200, 392
definition of 288	discordant twin pairs 208–9
future research 306–7	equal environments assumption 197–9, 248–9
limitations of current studies 306	gene-environment interaction consequences
prevention 306, 307	245–9
rates in follow-up studies of people with	results 199–200
schizophrenia 292–8	
research designs 289–90	unemployment rates, service planning and 420-1
risk factors 277, 298-306	urban effects 49-55, 75, 432
adverse life events 303-4	historical context 49-50
comorbidity 302-3	migrants 62
cultural factors 298–9	possible explanations for increased risk 53–5
duration, course and phase of schizophrenia	drug abuse 54
299–302	infectious disease 53-4
family factors 304	obstetric complications 53
previous suicidality 303	psychosocial stress 54
schizophrenia subtypes and symptoms 302	social class 53
treatment-related factors 304–6, 307	social isolation 54–5
schizophrenia prevalence among general	recent studies 50-2
population suicides 290–2	season of birth and 57
service planning implications 415	service planning implications 419, 420
sociodemographic factors 299	timing of exposure 52–3
sulcal cerebrospinal fluid volume 262–3, 264	timing of enposare 52 5
Swedish Conscript Cohort 114	vaccinations
symptoms	MMR vaccine, autism and 9
dimensions of 207–8, 390–8	prenatal infection exposure and 41
contrast in aetiology and familial morbid risk	ventricular cerebrospinal fluid to brain ratio 258,
392–3	<u> •</u>
	259, 260
contrast in course and outcome 393–6	very-late-onset schizophrenia 167
contrast in neuropsychology 396–8	course of disease 181
psychopathological contrast 390–1	outcome 181
distribution of 369	phenomenology 172–3
grouping 377–8	prevalence rates 170
onset of disease 137–8	risk factors
prevalence of 369–73	genetic 174
delusions 371–3	neurocognitive impairment 179–80
hallucinations 370-1, 372-3	premorbid personality 176
prodromal	sensory impairment 176
assessment of 125–8	social isolation 177
validation of 129–31	structural brain abnormalities 178
service planning implications 415-16	treatment issues 182–3
suicide risk factors 302	see also onset of disease



### 454 Index

violence 343–57
community prevalence studies 349–50
future research 357
methodological limitations of violence studies 350–4
confounding 353–4
definition and measurement of exposure 350
definition and measurement of outcome 351–2
selection bias 352–3

predictors of violent behaviour 354–5
risk of violence attributable to schizophrenia
355–7
studies estimating the prevalence of
schizophrenia in those who have
committed violent acts 348–9
studies estimating the prevalence of violent acts
among schizophrenics 343–8
cohort studies 345–8
cross-sectional studies 344–5
substance abuse and 335